Inside Bluepharma's New Complex Injectables Facility: From Innovation to GMP Manufacturing
At Bluepharma, we believe that innovation only creates value when it can be translated into robust pharmaceutical development and industrial manufacturing.
As part of our continued investment in Advanced Therapeutic Modalities, we are pleased to share a new video showcasing our dedicated facilities developed under the CInTech initiative - a technological hub focused on the innovation, translation and industrialization of complex injectable medicines.
Building the Infrastructure for the Next Generation of Medicines
The pharmaceutical landscape is rapidly evolving towards increasingly sophisticated products, including:
- Therapeutic peptides;
- RNA-based medicines;
- Antibody-Drug Conjugates (ADCs);
- Nanoparticle-based formulations;
- Highly potent compounds;
- Lyophilized sterile products.
These advanced modalities require specialized development expertise, high-containment capabilities and dedicated GMP infrastructures.
To address these needs, Bluepharma is expanding its capabilities through new dedicated centers focused on the development, scale-up and GMP manufacturing of complex injectable products.
An Integrated Platform
Our new infrastructure combines three complementary dimensions:
- Development & Process Engineering: Supporting formulation development, process optimization and scale-up activities for complex injectable medicines.
- Advanced Analytical & Characterization Services: Specialized capabilities for the development, analysis and characterization of complex injectable formulations, including lyophilized products.
- GMP Manufacturing: A highly specialized manufacturing environment designed to support clinical and registration batches for advanced pharmaceutical products.
Designed for Advanced Therapeutic Modalities
The platform is intended to support a broad range of pharmaceutical technologies and molecular classes, including:
- Liposomal formulations;
- Lipid nanoparticles (LNPs);
- Polymeric nanoparticles (PNPs);
- Sterile suspensions and emulsions;
- Lyophilized injectables;
- Small molecules;
- Peptides;
- Nucleic acids;
- Biologics.
Through this integrated approach, Bluepharma aims to provide flexible support from early development through GMP manufacturing.
We invite you to explore our new video and discover how Bluepharma is creating the infrastructure needed to accelerate the development and industrialization of the next generation of complex injectable medicines.
If you are developing complex injectable products, advanced formulations or next-generation therapeutic modalities, we would be pleased to discuss how Bluepharma can support your development and manufacturing journey.